Why Mesa Laboratories, Inc.’s (MLAB) Stock Is Up 6.52%
As of Tuesday, November 10, Mesa Laboratories, Inc.’s MLAB share price has surged by 6.52%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $756.5 | $3,423.9 | 43% |
|
| Shares Out (Mil) | 5.8 | 107.2 | 15% |
|
| Institutional Ownership | 96.8% | 89.3% | 71% |
|
| Float (Mil) | 5.0 | 77.0 | 12% |
|
| Beta | 1.08 | 1.17 | 64% |
|
| Avg Daily Volume (000s) | 127 | 1,071 | 38% |
|
| Price Change (52-week) |
82.0% | 81.6% | 94% |
|
| Growth | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.2% | 7.5% | 69% |
|
| Net Income (5yr) | 15.2% | (12.1%) | 64% |
|
| EPS (5yr) | 13.6% | 2.1% | 54 |
|
| Dividends (5yr) | 0.0% | 0.0% | 72% |
|
| Cash Flow (5yr) | (14.9%) | (14.9%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $3.010 | $11.520 | $12.170 | |
| Month Ago EPS | $2.710 | $9.950 | $10.270 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $2.710 | $9.950 | $10.270 | |
| Year/Year Chg | 301.3% | 852.1% | na | |
| Financials | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $251 | $811 | 34% |
|
| Net Income (TTM) (Mil) | $7 | ($19) | 43% |
|
| EPS (TTM) | $1.194 | ($0.300) | 63% |
|
| Operating Cash Flow (TTM) (Mil) | $52 | $52 | 46% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $3 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $142 | $252 | 46% |
|
| Enterprise Value (Q1) (Mil) | $907 | $3,486 | 40% |
|
| Valuation | MLAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.88 | 3.38 | 76% |
|
| P/E | 114.0 | 35.5 | 95% |
|
| Dividend Yield | 0.5% | 0.0% | 62% |
|
| PEG (5yr hist) | 8.4 | 6.6 | 93% |
|
| Ratios | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.8% | 47.8% | 77% |
|
| Net Margin | 2.7% | (3.0%) | 39% |
|
| ROA | 1.6% | (5.4%) | 52% |
|
| ROE | 3.6% | (5.2%) | 40% |
|
| Liabilities to Assets | 52.3% | 41.5% | 45% |
|
| F-Score | 7 | 5 | 82% |
|
Mesa Laboratories, Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors